Premium
Hyoscine butylbromide mode of action on bowel motility: From pharmacology to clinical practice
Author(s) -
Corsetti Maura,
Forestier Sylvie,
Jiménez Marcel
Publication year - 2023
Publication title -
neurogastroenterology and motility
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.489
H-Index - 105
eISSN - 1365-2982
pISSN - 1350-1925
DOI - 10.1111/nmo.14451
Subject(s) - antispasmodic , mode of action , medicine , clinical practice , action (physics) , pharmacology , clinical trial , intensive care medicine , biology , physical therapy , toxicology , physics , quantum mechanics
Abstract Background Hyoscine butylbromide (HBB) has been available for use as an antispasmodic since 1951 and is indicated for the treatment of abdominal pain associated with cramps. A previous review in 2007 summarized the evidence on the mode of action of HBB in vitro and in vivo in both animal and human studies. However, since then, novel publications have appeared within the literature and also our knowledge of what represents normal motility in humans has evolved. Purpose This review is the result of the collaboration between a basic scientist and clinicians with the aim of providing an updated overview of the mechanisms of action of HBB and its clinical efficacy to guide not only use in clinical practice, but also future research.